Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 8/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876113 | 0.88 | KCNH2 (0.36) | KCNH2HRH3GNRHR | |
| SCHEMBL3001810 | 0.81 | ACHE (0.38) | GNRHR | |
| SCHEMBL4868432 | 0.81 | KCNH2 (0.34) | KCNH2HRH3PDK1 | |
| SCHEMBL4866922 | 0.79 | GRIN2B (0.36) | KCNH2HRH3KDM4EALDH1A1 | |
| SCHEMBL4878217 | 0.74 | MAPT (0.39) | LMNAMAPTALDH1A1 | |
| SCHEMBL4875057 | 0.74 | KCNH2 (0.35) | KCNH2HRH3ALDH1A1 | |
| SCHEMBL4875248 | 0.73 | PTGS2 (0.35) | KCNH2HRH3LMNAKDM4EALDH1A1 | |
| SCHEMBL4878159 | 0.73 | KCNH2 (0.34) | KCNH2HRH3COMT | |
| SCHEMBL4876042 | 0.72 | KDM4E (0.36) | KCNH2HRH3COMTKDM4EHTT | |
| SCHEMBL3931430 | 0.71 | KDM4E (0.35) | KCNH2HRH3COMTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KCNH2 2647/4885HRH3 4258/4885GNRHR 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.